Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Liminatus Pharma Inc. (LIMN) vs Nuvilex Inc. (PMCB)

Liminatus Pharma Inc. and Nuvilex Inc. are both Biotechnology companies. Liminatus Pharma Inc. is the larger, with a market value of $5.6M against $4.9M — 1.1× the size. Across the 9 metrics below, Nuvilex Inc. leads on 5 and Liminatus Pharma Inc. on 4.

Valuation

Metric LIMN PMCB Biotechnology median
P/E n/m n/m 7.88
P/S n/m n/m 11.47
P/B 13.53 0.17 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 3.67 0.74
EV/Sales n/m n/m 10.73
Earnings yield (559.52%) (509.84%) (28.84%)
Free cash flow yield (97.71%) (224.12%) (23.03%)

Profitability

Metric LIMN PMCB Biotechnology median
Gross margin — 95.64% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 294.43% (58.04%) (57.72%)
Return on assets (471.47%) (50.43%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LIMN PMCB Biotechnology median
Revenue growth (TTM) — (71.06%) 5.64%
EPS growth (last fiscal year) (112.19%) (186.83%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LIMN PMCB Biotechnology median
Debt to equity 4.80 0.00 0.00
Current ratio 1.12 40.29 4.73
Net debt to EBITDA (0.37) 5.41 0.96

Dividend

Metric LIMN PMCB Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric LIMN PMCB Biotechnology median
Market cap 5.61m 4.90m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack